靶向滋养层细胞表面抗原2(TROP2)的新型抗体药物偶联物datopotamab deruxtecan在卵巢癌中的临床前活性
在卵巢癌细胞系和异种移植模型中评估靶向TROP2的抗体药物偶联物Dato-DXd的临床前活性。TROP2高表达(3+)和中度表达(2+)的细胞系对Dato-DXd更敏感,Dato-DXd可诱导DNA双链断裂、凋亡和ADCC,并在TROP2 3+异种移植模型中抑制肿瘤生长、延长生存且毒性轻微。
要点
- TROP2高表达(3+)和中度表达(2+)的上皮性卵巢癌细胞系对Dato-DXd敏感性高于TROP2阴性肿瘤。
- Dato-DXd暴露的TROP2阳性上皮性卵巢癌细胞DNA双链断裂和Annexin-V阳性率增加(分别p=0.001和p=0.016)。
- Dato-DXd在TROP2 3+异种移植模型中抑制肿瘤生长并延长生存,毒性轻微。
核心结论
- Dato-DXd在TROP2高表达卵巢癌中显示出有前景的临床前活性,未来有必要在卵巢癌患者中开展临床试验。
研究设计与样本
- 临床前研究:体外使用流式细胞术检测Dato-DXd对TROP2表达可变的上皮性卵巢癌原代细胞系的细胞活力,并检测DNA双链断裂;体内在TROP2过表达异种移植模型中测试Dato-DXd的抗肿瘤活性。
主要发现
- TROP2过表达(3+)和中度表达(2+)的上皮性卵巢癌细胞系对Dato-DXd的敏感性高于TROP2阴性肿瘤。
- Dato-DXd暴露的TROP2阳性上皮性卵巢癌与暴露于非结合偶联物的肿瘤细胞相比,DNA双链断裂增加(p=0.001),Annexin-V阳性增加(p=0.016)。
- Dato-DXd在外周血淋巴细胞存在下诱导显著的抗体依赖性细胞毒性(ADCC)。
- Dato-DXd对低TROP2表达的上皮性卵巢癌细胞系活性可忽略,但在体外与TROP2 3+肿瘤细胞混合时对低/可忽略TROP2的肿瘤细胞显示出显著的旁观者杀伤效应。
- Dato-DXd在过表达TROP2(3+)的上皮性卵巢癌细胞系来源异种移植模型中抑制肿瘤生长,与对照相比延长生存,且毒性轻微。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Epithelial ovarian cancer (EOC) is associated with the highest gynecologic cancer mortality. The development of novel, effective combinations of targeted therapeutics remains an unmet medical need. We evaluated the preclinical activity of datopotamab deruxtecan (Dato-Dxd), a novel TROP2 targeting antibody drug conjugate (ADC) in ovarian cancer cell lines and xenografts with variable TROP2 expression. METHODS: In vitro cell viability with Dato-DXd was assessed using flow-cytometry based assays against a panel of EOC primary cell lines with variable TROP2 expression. Fluorescent anti-phospho-histone H2A.X antibody was used to detect dsDNA breaks by flow-cytometry. The in vivo antitumor activity of Dato-DXd was tested in TROP2 overexpressing xenografts. RESULTS: TROP2 overexpressing (3+) and moderate (2+) expressing EOC cell lines demonstrated higher sensitivity to Dato-DXd when compared to TROP2 negative tumors. Dato-DXd exposed TROP2+ EOC demonstrated increased dsDNA breaks and Annexin-V positivity (a marker of apoptosis) when compared to tumor cells exposed to the non-binding conjugate (p = 0.001 and p = 0.016, respectively). Dato-DXd induced significant antibody-dependent cellular cytotoxicity (ADCC) in the presence of peripheral-blood-lymphocytes. While negligible activity was detected against EOC cell lines with low TROP2 expression, Dato-DXd demonstrated significant bystander killing against tumor cells with low/negligible TROP2 when such cells were admixed with TROP2 3+ tumor cells in vitro. Dato-DXd showed tumor growth suppression against EOC cell line derived xenograft models that overexpress TROP2 at 3+ levels, prolonging survival when compared to controls, with minimal toxicity. CONCLUSION: Dato-DXd shows promising preclinical activity against TROP2 overexpressing ovarian cancers. Future clinical trials in ovarian cancer patients are warranted.
引用
- McNamara B, Greenman M, Bellone S, et al. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecol Oncol. 2024. PMID: 38981151. doi:10.1016/j.ygyno.2024.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。